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INTRODUCTION 
Medullary thyroid carcinoma (MTC) represents 3% to 10%
of most institutional series of thyroid cancers; hereditary MTC
accounts for 25% to 30% of these patients (1, 2). Hereditary
MTC is divided into three clinical subtypes depending on
the presence or absence of tissue-specific tumors, phenotypic
characteristics and the number of affected family members:
familial MTC (FMTC), multiple endocrine neoplasia (MEN)
type 2A and MEN type 2B (3, 4). FMTC accounts for 5%
to 15% of hereditary MTC cases. It is defined as the presence
of MTC in a kindred with four or more affected members,
and with no clinical or biochemical evidence of adrenal or
parathyroid gland involvement either in the affected mem-
bers or in the available first degree relatives (5). FMTC rep-
resents a less aggressive form of hereditary MTC, and it has
a corresponding older age at onset, often between 20 and 40,
compared to MEN 2A and MEN 2B (6, 7). 
Hereditary MTC is caused by autosomal dominant gain-
of-function mutations in the RET proto-oncogene (8). A
germline mutation in the RET proto-oncogene, which en-
codes for a transmembrane tyrosine kinase receptor, predis-
poses individuals to develop MTC. An identifiable RET muta-
tion can be detected in about 85% of FMTC families (9). The
majority of germline mutations in FMTC have been found
in exons 10 and 11 of the RET proto-oncogene, specifically
within the cysteine codons 609, 611, 618, 620, and 634. In
addition, mutations in the intracellular domain of the protein
have been described at: 768, 790, 791 in exon 13, V804M,
844 in exon 14, 891 in exon 15, and 912 exon 16 (3, 7, 10).
Mutations at codons 532, 533 (exon 8), 768, 844, and 912
have been identified only in families with FMTC (10-12). 
Many studies of RET mutations in heritable MTC have
been published in different countries. However, there are few
reports of these mutations in Korean families with FMTC.
In this study we screened members of a large Korean family
that had a history of FMTC by genetic analyses, and propose
a therapeutic approach for managing the disorder. 
MATERIALS AND METHODS
The pedigree of the family is shown in Fig. 1. This large
family consists of three generations with a total of 30 individ-
uals. Twenty-nine members of the family underwent genetic
testing in 2004. There was a history of MTC in eight mem-
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Familial medullary thyroid carcinoma (FMTC) is caused by autosomal dominant
gain-of-function mutations in the RET proto-oncogene. An identifiable RET muta-
tion can be detected in about 85% of FMTC families. The majority of germline muta-
tions in FMTC have been found in exons 10 and 11 of the RET proto-oncogene,
specifically within the cysteine codons 609, 611, 618, 620, and 634. We screened
members of a large Korean family that had a history of FMTC by genetic analyses,
and propose a therapeutic approach for managing the disorder. We report a RET
mutation in exon10, codon 618 that causes substitution of a cysteine by a serine in
the cysteine-rich domain of the RET receptor in a three-generation FMTC family
composed of 30 members with 11 carriers. Nine of the gene carriers were clinical-
ly affected. The FMTC with cysteine RET mutations found in the Korean population
is consistent with the clinical pattern reported worldwide; to date there have been
no ethnic differences identified for FMTC. Our results suggest that this genetic pro-
file might be associated with usually aggressive clinical course with regional lymph
node metastasis but late onset of MTC.
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bers of the family. Five patients were diagnosed with MTC
before genetic testing (II-1, II-4, III-2, III-8, III-14). Other
three patients were diagnosed after genetic testing and clin-
ical screening (II-2, III-1, III-13). The index case was a 67-yr-
old woman (II-1) who had a total thyroidectomy with mod-
ified radical neck dissection bilaterally, at the age of 48 yr, for
an anterior neck mass that presented 10 yr earlier. The his-
tological examination showed the presence of MTC in both
lobes and microscopic metastatic disease in 14 lymph nodes
in the central and both lateral compartments. There was no
clinical or biochemical evidence of pheochromocytoma, para-
thyroid disease or other associated clinical features attribut-
ed to MEN2. On her last follow-up visit, 23 yr after her ini-
tial diagnosis, there was no radiological evidence of recurrent
or metastatic disease, despite an elevated serum calcitonin
level of 593.5 pg/mL (normal range, <10 pg/mL). The index
patient and at-risk family members had RET mutation genet-
ic screening. Prior to obtaining the samples, all individuals
included in the study were fully informed about the study
and consents were obtained. After the genetic screening, we
recommended further evaluation for gene carriers. However,
they refused further biochemical testing and agreed only to
thyroid ultrasound examinations. 
DNA analysis
For identification of RET germline mutations, genomic
DNA was purified from peripheral blood lymphocytes using
the QIA quick PCR purification kit (Qiagen, Hiden, Ger-
many). DNA of the index case (II-1) was first screened by
looking for RET proto-oncogene mutations in exons 10, 11,
13, 14, 15, and 16, where most of the RET mutations are
found in FMTC. For the rest of the individuals, only exon
10 was analyzed. Genomic DNA was amplified by the poly-
merase chain reaction with oligonucleotide primers for exons
10, 11, 13, 14, 15, and 16. Single-strand conformation poly-
morphism analysis and direct sequencing were performed
on an automated DNA sequencer (ABI PRISM 310, Perkin
Elmer, Foster City, CA, USA). 
RESULTS
Genetic analysis of the index case revealed a missense TGC
→AGC mutation at codon 618 in exon 10 of the RET proto-
oncogene. This transversion leads to the substitution of cys-
teine with serine (Fig. 2). Direct sequencing of the RET exon
10 polymerase chain reaction products, from genomic DNA
of family members, showed that 11 of 29 members were car-
riers for this mutation, and 18 were unaffected. Clinical fea-
tures of the mutation of the carriers are shown in Table 1. Nine
of the gene carriers were clinically affected. Eight (II-1, II-2,
II-4, III-1, III-2, III-8, III-13, and III-14) of them underwent
surgery and one (III-12) has been scheduled for surgery. The
mean age at surgery was 37 yr (range, 18 to 67). The youngest
patient to present with MTC and lymph node metastases was
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Fig. 1. Pedigree of the family with familial medullary thyroid carcinoma. Circles and squares denote female and male family members, res-
pectively.
Fig. 2. The sequence TGC encoding cysteine in the wild-type is
changed to the sequence AGC encoding serine in codon 618 on
exon 10 of the RET proto-oncogene.
Wild-type, codon 618, TGC (Cys) Wild-type, codon 618, TGC (Cys) Mutant-type, codon 618, AGC (Ser)228 J. Jung, S. Uchino, Y. Lee, et al.
18-yr old. Seven patients had bilateral MTC. Seven patients
with MTC had lymph node metastases including four later-
al neck node metastases. Median follow-up period was 10 yr.
There was no case with disease recurrence or death during
follow-up. The brother of the index case (II-5) exhibited in-
creased serum calcitonin in response to pentagastrin stimu-
lation and underwent a total thyroidectomy at 45 yr of age;
the histology examination showed normal thyroid tissue. He
was confirmed not to have a RET mutation. Two family mem-
bers positive for the RET mutation, a 37-yr-old man (III-3)
and a 12-yr-old girl (IV-3), are asymptomatic and have no
evidence of disease by thyroid ultrasound; they have refused
further biochemical investigation. 
DISCUSSION
We report a RET mutation in exon 10, codon 618 that
causes substitution of a cysteine by a serine in the cysteine-
rich domain of the RET receptor in a three-generation FMTC
family composed of 30 members with 11 carriers. Approxi-
mately 85% of families with FMTC have an identifiable RET
mutation (9). In general, FMTC patients have the same muta-
tions as patients with MEN2A, but they are more evenly dis-
tributed among cysteines 618, 620, and 634 each accounting
for 25% to 35% of the mutations. Five percent to 10% of
FMTC patients have a mutation in an intercellular domain,
that is, in codons 768, 804 or 891 (9, 12-15). 
It has been established that specific RET mutations predict
the phenotypic expression of the disease. It has been report-
ed previously that mutations at codon 618 are associated with
MEN2A, FMTC and Hirschsprung disease (HSCR1). Muta-
tions in this codon are associated with low transforming activ-
ity of RET and may be associated with milder forms of the
disease (16, 17). In the kindred that we have described here,
all of the affected patients had MTC as the sole clinical find-
ing and did not have any evidence of adrenal or parathyroid
involvement on screening. The median age at surgery was
27 yr (range, 18 to 67). The median age at the time of the
development of MTC, in this study in FMTC patients, was
similar to the age reported for previous FMTC families. Among
eight patients with MTC, seven had bilateral cancer and lym-
ph node metastases including four lateral neck node metas-
tases. The FMTC with cysteine RET mutations found in the
Korean population is consistent with the clinical pattern re-
ported worldwide; to date there have been no ethnic differ-
ences identified for FMTC.
Kouvaraki et al. (3) reported that RET mutations can be
stratified into three groups (levels 1 to 3) based on the bio-
logical aggressiveness of MTC observed in patients with these
mutations. Level II mutations are considered high risk, and
correspond to MEN2A and some FMTC mutations, includ-
ing codons 611, 618, 620, and 634. Carriers of high-risk
RET mutations develop MTC starting from the age of one
year (codon 634) and five years (codon 611, 618, and 620),
lymph node metastasis from the first decade (codon 634) and
the second decade (codon 611, 618, and 620), and distant
metastases generally from the third decade (18). Current guide-
CT, calcitonin; M, male; F, female; TT, total thyroidectomy; MRND, modified radical neck dissection; ND, neck dissection; MTC, medullary thyroid can-
cer; Rt, right; Lt, left; LN, lymph node.
Case
Sex/age
(yr)
Age at
surgery
(yr)
Follow-up 
CT (pg/mL, 
<10 pg/mL)
TNM 
staging
LN 
metastasis 
Tumor  Histology
Preop. basal 
CT (pg/mL,
<10 pg/mL)
Type of operation 
II-1 F/72 48 TT with  MTC Rt 1.8 cm  Yes (14/38) T3N1M0 593.5
central and both lateral MRND Lt 6.5 cm Stage III
II-2 M/68 67 1,035.7 TT with central ND MTC Rt 0.3 cm Yes (9/13) T2N1M0 1.3
Lt 2.5 cm Stage III
II-4 M/59 42 1,000 TT with central ND MTC Rt 1.5 cm  No (0/6) T2N0M0 2.2
Lt 1 cm Stage II
III-1 M/49 49 208.9 TT with central ND MTC Rt 0.3 cm Yes (11/13) T2N1M0
Lt 1.2 cm Stage III
III-2 F/35 18 TT with MTC Rt 3.5 cm  Yes (8/23) T2N1M0
central and left lateral MRND Lt 0.6 cm Stage III
III-8 F/32 24 1,900 TT with  MTC Rt 0.8 cm  Yes (27/57) T2N1M0 133.7
central and left lateral MRND Lt 3 cm Stage III
III-12 F/28 Scheduled
III-13 M/29 27 143.2 TT with central ND MTC Rt 1.0 cm Yes (2/7) T1N1M0 0.2
Lt 0.5 cm Stage III
III-14 M/27 19 TT with  MTC Lt 4.5 cm Yes (13/38) T3N1M0 286.3
central and left lateral MRND Stage III
Table 1. Clinical characteristics of 9 gene carriers with medullary thyroid carcinomaFamilial Medullary Thyroid Cancer with Cys618Ser RET Germline Mutation 229
lines for the treatment of patients with level two, high-risk
group mutations, recommend prophylactic total thyroidec-
tomy before the age of five years. No agreement has been
reached about the need for additional central lymph node
dissection in patients with these mutations. 
The 12-yr-old granddaughter (IV-3) in this family is being
carefully monitored at the time of preparation of this report
to determine the appropriate timing of thyroidectomy. Such
surgery has not yet been performed because of the potential
risks and complications associated with a thyroidectomy, the
lack of radiological signs of development of MTC, and the
possibility of slow growth of MTC associated with a codon
618 mutation. The other family members positive for the
RET mutation, a 37-yr-old man (III-3), is asymptomatic and
have no evidence of disease by thyroid ultrasound. We have
recommended prophylactic thyroidectomy, however, to date
they have refused the procedure.
In summary, we report here an extracellular mutation of
the RET proto-oncogene that was identified in a large Korean
family with FMTC. The mutation substituted a cysteine for
a serine in codon 618 of exon 10 (C618S, TGC to AGC). Our
results suggest that this genetic profile might be associated
with usually aggressive clinical course with regional lymph
node metastasis but late onset of MTC.
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